semaglutide type 2 diabetes drug improves weight loss, blood sugar in certain Type 1 patients with obesity Can Type 1 and Type

Its doseresponse relationships with respect to side effects, safety, and efficacy for the treatment of obesity.

GLP-1 RAs seem to promote bone formation while inhibiting bone resorption

Emotional changes during GLP-1 therapy are real but often temporary

Discover 5 ways to support your satiety hormones and quieten the "food noise"

Our product has officially passed the FDA's rigorous regulatory review, which includes in-depth scientific evaluation, clinical validation, and quality assurance testing

A four-minute drive north of the Illinois-Wisconsin border in 'America's Dairyland,' Eli Lilly is staking one of its largest-ever manufacturing bets to continue its dominance in obesity drugs and support a deep pipeline of next-generation medicines for the most lucrative pharmaceutical market.